The study by Na et al. contained 100 NSCLC patients, including 53 ADC and 47 non-ADC patients regardless of tumor stage; the study was also conducted in Korea, and the EGFR mutation rate was 21%. This evidence concerns the gene EGFR and non-small cell lung carcinoma.